Member access

4-Traders Homepage  >  Shares  >  Mercado Continuo Espanol  >  Grifols SA    GRF   ES0171996012

GRIFOLS SA (GRF)

52
 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Mercado Continuo Espanol
01/20/2015 01/21/2015 01/22/2015 01/23/2015 01/26/2015 Date
35.19(c) 35.345(c) 35.045(c) 35.61(c) 36.63(c) Last
861 089 905 089 935 211 1 149 709 1 100 321 Volume
+1.03% +0.44% -0.85% +1.61% +2.86% Change
More quotes
Company
Grifols SA is a vertically integrated global producer of plasma derivatives.Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers.The company operates through four segments: Bioessence,... 
Sector
Pharmaceuticals
Calendar
02/26Earnings Release
More about the company
Surperformance© ratings of Grifols SA
Trading Rating : Investor Rating :
More Ratings
Chart GRIFOLS SA
Duration : Period :
Grifols SA Technical Analysis Chart | GRF | ES0171996012 | 4-Traders
Full-screen chart
Financials (€)
Sales 2014 3 360 M
EBIT 2014 869 M
Net income 2014 468 M
Debt 2014 2 991 M
Yield 2014 1,52%
Sales 2015 3 617 M
EBIT 2015 943 M
Net income 2015 531 M
Debt 2015 2 815 M
Yield 2015 1,82%
PER 2014 24,13
PER 2015 21,10
EV / Sales 2014 4,32x
EV / Sales 2015 3,96x
Capitalization 11 523 M
More Financials
Latest news on GRIFOLS SA
01/08 GRIFOLS : new immunoglobulin purification plant in the United States receives FD..
01/05 GRIFOLS : receives FDA approval for its new purification plant to produce Gamune..
01/02 GRIFOLS : receives FDA approval for its new purification plant to produce Gamune..
01/02 GRIFOLS : Johnston students to 'Discover the Plasma' through Grifols partnership
2014 GRIFOLS SA : ex-dividend day for interim dividend
2014 GRIFOLS : introduces new 40-g IVIG vial size for GAMUNEX-C
2014 ARADIGM : Announces Third Quarter 2014 Financial Results
2014 GRIFOLS : contributes to river restoration projects
More news
Sector news Biopharmaceuticals
07:08p JOHNSON & JOHNSON : Former FDA commissioner might testify against J&J in Philly ..
05:37pDJU.S. to Give $1 Billion to Fund Immunizations -- 2nd Update
05:31p ACTAVIS : Registration Statement for Pending Acquisition of Allergan Declared Ef..
Plus d'actualités du secteur Biopharmaceuticals


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF